Skip to the main content.
Facebook Instagram Linkedin X YouTube Medium

megamenu-services

 

Turn Vision into Velocity with the Innovation CRO

Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.

All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.

Explore our Services

megamenu-solutions-expertise

 

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Solutions

Expertise

megamenu-company-2

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Explore our Company

Gary Keeler

3 min read

DTx Part II: Building Evidence-Based Value Propositions for Digital Therapeutics

Gary Keeler: Feb 4, 2020 11:38:33 AM

In DTx Part I: Identifying Optimal Payment Models for Digital Therapeutics we identified several potential payment models for monetizing the value of DTx. While establishing payment mechanisms is essential for capturing the value of DTx products,...

Commercialization
Read More

1 min read

Navigating the Italian HTA Process: Essentials to a Favorable Review

Gary Keeler: Jan 6, 2020 11:49:53 AM

From November 1, 2016 to September 1, 2019, the Italian Medicines Agency, AIFA (Agenzia Italiana del Farmaco) evaluated a total of 166 Dossiers – 28...

Read More

2 min read

DTx Part I: Identifying Optimal Payment Models for Digital Therapeutics

Gary Keeler: Dec 3, 2019 11:37:51 AM

According to the Digital Therapeutics Alliance (DTA), digital therapeutics (DTx) are products that deliver “software-generated therapeutic...

Commercialization
Read More

1 min read

Possibility for Examination to be Included in the SHI Fee Scale Brings More Certainty for Reimbursement for New Diagnostics in Germany

Gary Keeler: Sep 11, 2019 12:54:33 PM

Manufacturers can now have more certainty about the process of inclusion of a new laboratory, new human-genetic, or new tumor-genetic diagnostics in...

IVD Commercialization
Read More
Prev 1 2 3 4 5